Diabetes is one of the priority ... a range of therapeutics from classical small drug molecules to novel agents such as oligonucleotide and mRNA therapies. Approaches are being developed that ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Rather, it brings with it platform capabilities in formulations of mRNA drugs, including lipid nanoparticles used to deliver them safely to target tissues, as well as additional manufacturing ...

Now, an analysis of studies has found that newer medications for type 2 diabetes may help reduce the risk of complications, particularly cardiovascular disease, in some people with type 2 diabetes.